Dr Sam Abraham
Murdoch University, Western Australia
In 2006, Doctor Sam Abraham received his BSc in Zoology from Mahatma Gandhi University in India. Shortly after, he moved to Australia in pursuit of higher education and joined the University of Wollongong to undertake a Masters in Biotechnology. Subsequently, he completed a PhD in Microbiology and Molecular Biology from the University of Wollongong (2012) undertaking his research at the Elizabeth MacArthur Agricultural Research Institute, New South Wales Department of Primary Industries. In 2012, he moved to the University of Adelaide to undertake a post-doctoral research fellowship in Antimicrobial Resistance with A/Prof Darren Trott. Alongside A/Prof Trott, he established the First National Network on Antimicrobial Resistance Surveillance in Australian Animals. In 2015, Doctor Abraham joined Murdoch University as an academic lecturer in veterinary and medical infectious diseases.
A/Prof Noleen Bennett
The Doherty Institute, Victoria
Associate Professor Noleen Bennett is a senior Infection Control Consultant employed at both the National Centre for Antimicrobial Stewardship and Victorian Healthcare Associated Infection Surveillance System Coordinating Centre. Her current roles include co-ordinating the annual Aged Care National Antimicrobial Prescribing Survey.
Dr Catriona Bradshaw
Monash University, Victoria
Catriona Bradshaw [MBBS(Hons), FAChSHM, PhD] is a senior sexual health consultant, Head of the Genital Microbiota and Mycoplasma Group at Melbourne Sexual Health Centre (Alfred Hospital) and an Associate Professor at the Central Clinical School, Monash University. Catriona focuses on clinical translational research to improve treatment and control of sexually transmitted infections, particularly Mycoplasma genitalium (MG), an STI which has developed resistance to available therapies and bacterial vaginosis, a common vaginal dysbiosis associated with adverse reproductive health outcomes including premature delivery. M. genitalium is associated with urethritis, PID and adverse reproductive sequelae in women and incurable infections are increasingly encountered. Her MG programme has been responsible for key advances that have provided new drug options and resistance-guided strategies which have been adopted internationally. Her current programme addresses urgent priorities to achieve and maintain high level cure and optimal antimicrobial stewardship. Her programme of research on bacterial vaginosis and maintenance of a health vaginal microbiota to optimise reproductive health. Her group is currently undertaking an NHMRC funded multicentre male partner treatment trial for women with bacterial vaginosis and, if effective, this strategy will have a global impact providing opportunities for the first time for long-term control and prevention of BC and sequelae such as pre-term birth. Catriona has a strong track record that translates into changes in policy and practice with over 220 publications.
Prof Kirsty Buising
The University of Melbourne, Victoria
Professor Kirsty Buising is an infectious diseases physician working for the Victoria Infectious Diseases Service (VIDS). She is Deputy Director of the National Centre for Antimicrobial Stewardship and chief investigator for the National Health and Medical Research Council (NHMRC) funded Centre for Research Excellence in Antimicrobial Stewardship. Kirsty also holds an appointment as a clinical research physician at VIDS, leading the research and development for the Guidance group. Kirsty serves on advisory groups at state, national and international levels in the areas of antimicrobial stewardship, guideline development and healthcare associated infection.
Dr Andrew Burke
Royal Brisbane and Womens' Hospital, Queensland
Andrew is an infectious diseases and thoracic physician at The Prince Charles Hospital in Brisbane. He has a research interest in the treatment of tuberculosis and non-tuberculosis mycobacteria. Andrew is involved in TB and NTM guideline development in Queensland and Australia and is undertaking a PhD through the University of Queensland, studying the pharmacokinetics of mycobacterial drugs in cystic fibrosis as well as quinolone prophylaxix for MDR-TB. He is a primary investigator in clinical studies of novel inhaled therapies for treatment failure pulmonary NTM infection.
Dr Louise Cooley
Royal Hobart Hospital, Tasmania
Dr Louise Cooley is an infectious diseases physician and clinical microbiologist, and Director of Microbiology and Infectious Diseases at the Royal Hobart Hospital, Tasmania. She is a member of the AGAR Executive Committee, Tasmanian representative on the Public Health Laboratory Network and Communicable Diseases Genomics Network, and a member of the National Centre for Infections in Cancer (NCIC) research group. Her clinical and research interests include antimicrobial resistance and surveillance, microbial genomics, epidemiology of influenza, epidemiology and management of infections in immunocompromised hosts, and antifungal stewardship in high risk patient groups.
Dr Chris Coulter
Pathology Queensland, Queensland
Chris Coulter is a Medical Microbiologist and Consultant Physician in Infectious Diseases. He is the Director of the Queensland Mycobacterium Reference Laboratory (Pathology Queensland) which is a World Health Organization Collaborating Centre for Tuberculosis Bacteriology and Supranational Reference Laboratory. He is also the Medical Advisor for TB and Infectious Diseases, Communicable Disease Branch , Department of Health Queensland. Chris is the jurisdictional member for Queensland for the National TB Advisory Committee having chaired this group 2014 – 2018. He has served on guideline and expert technical committees for WHO including published guidance on Xpert Ultra, Line probe assays for detection of TB drug resistance, new critical concentrations for second line agents and the PK/PD of medicines used to treat drug resistant TB.
Dr Kathryn Daveson
Australian Commission on Safety and Quality in Healthcare, Canberra
Dr Kathryn Daveson is an infectious diseases physician and the current Clinical Director at the Australian Commission on Safety and Quality in Health Care Antimicrobial Use and Resistance in Australia (AURA) program. She has jurisdictional level experience in both Queensland and ACT Health where she has worked in antimicrobial stewardship in addition to clinical infectious diseases from rural to tertiary healthcare settings. Her other interests are in health economics, antibiotic pharmacokinetics and pharmacodynamics, infection control and the immunocompromised host.
Prof Josh Davis
John Hunter Hospital, New South Wales
Prof Josh Davis is an infectious diseases physician at John Hunter Hospital in Newcastle and a senior research fellow at the Menzies School of Health Research in Darwin. He has research interests in clinical trials, S. aureus bacteraemia, and bone and joint infection. Josh is the current president of ASID.
Dr Claire Dendle
Monash University, Victoria
Claire Dendle is an Infectious Diseases physician and the Director of the Infection and Immunity Service at Monash Health. Claire’s research interests include vaccination, prevention of infection in immunocompromised patients as well as the use of immunological biomarkers to determine the net state of immunocompromise. Claire is interested and involved in undergraduate education at Monash University and is the Director of Physician Training at Monash Health.
Dr Maryza Graham
Monash Health, Victoria
Dr Maryza Graham is a Clinical Microbiologist and Infectious Diseases Physician at Monash Health, Victoria's largest health service. Maryza has been a member of the RCPA Microbiology Advisory Committee for the past 9 years and is Chair of the National RCPA Selective Reporting of Antimicrobials Guidelines Committee.
Dr Jon Iredell
cal Centre, Melbourne. Since 2000, Prof. Grayson has been Director of Infectious Diseases and Microbiology, Austin Health, and PRofessor of Infectious Diseases, Department of Medicine, The University of Melbourne.
The University of Sydney, New South Wales
Jon is a physician and microbiologist based at Westmead Hospital and the University of Sydney, recent past-president of the Australian Society of Microbiology and chair of the Gram-negative Antimicrobial Surveillance Committee for AGAR. His work into sepsis and antimicrobial resistance has been continuously funded by the NHMRC since 2006 and his main current research interests are in the recognition and proactive management of risk from infection in the critically ill.
Dr Adam Jenney
The Alfred Hospital, Victoria
Adam Jenney is a clinical microbiologist and infectious diseases physician at the Alfred Hospital in Melbourne. He has a keen interest in ICU infections, and the antimicrobial stewardship possibilities that they create, which originated from working with Klebsiella pneumoniae. He enjoys teaching undergraduates in Melbourne and postgraduate students at Fiji National University where he holds an honorary appointment in the Department of Medical Sciences.
A/Prof Charlene Kahler
The University of Western Australia, Western Australia
Associate Professor Charlene Kahler has worked in the field of molecular microbiology over a 30 year career focusing on understanding the pathogenesis of Neisseria gonorrhoeae and Neisseria meningitidis. She has worked with the Departments of Health in Western Australia and South Australia examining intervention strategies such as vaccination against meningococcal disease and the spread of antimicrobial resistance in N. gonorrhoeae. She is also the Head of Division of Infection and Immunity and the Deputy Director of the Marshall Center in the School of Biomedical Sciences at the University of Western Australia. She is an Honorary Research Fellow at the Telethon Kids Institute and in 2019 she became a UWA Innovation Fellow in recognition for her capability and motivation to grow innovation and entrepreneurship.
Dr Tony Korman
Monash Health, Victoria
Tony Korman is the Director of Infectious Diseases and Director of Microbiology at Monash Health, Victoria's largest health service, and Infection theme leader, Centre for Inflammatory Diseases, and Adjunct Clinical Professor, Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University.
A/Prof Steven McGloughlin
Monash University, Victoria
Biography to follow.
Dr Orla Morrissey
Alfred Health, Victoria
Doctor Orla Morrissey was awarded, with honours, bachelors degrees in Medicine and Surgery in 1992 from University College Cork, National University of Ireland. She did her basic physician training at St Vincent's Hospital, Melbourne, and her advanced training in Infectious Diseases at the Alfred Hospital, which resulted in the award of Fellowship of the Royal Australasian College of Physicians in 2002. Dr Morrissey was also awarded a Graduate Diploma in Clinical Epidemiology in 2005. In 2009, she was awarded a PhD for her research into the development of new antifungal strategies for the management of invasive aspergillosis. Dr Morrissey was appointed in April 2009 to develop and lead an innovative Consult Service for the Immunocompromised Host within the Infectious Diseases Unit, Alfred Hospital, and as Adjunct Senior Lecturer in the Departments of Medicine and Clinical Haematology, Monash University. She also leads a clinical- and laboratory-based research program examining pre-emptive treatment strategies for invasive aspergillosis, different prophylactic regimens for invasive fungal infections (IFI), new surveillance strategies, trends in antifungal resistance, molecular epidemiology and host- and pathogens-related risk factors for IFI. She is involved in a number of national and international studies and has received over AU$2.5M in NHMRC, Cancer Council and industry funding, is on the steering committee for 3 PhD students and has supervised 1 Advanced Medical Science student. Dr Morrissey is the current co-chair of Australia and New Zealand Mycology Interest Group (ANZMIG).
Prof David Murdoch
The University of Otago, New Zealand
Professor David Murdoch is Dean and Head of Campus at the University of Otago, Christchuch. A clinical microbiologist and infectious diseases physican by background, his main research interests are the epidemiology, diagnosis and prevention of respiratory tract infections, pneumococcal disease, legionellosis, bloodstream infections, and the role of vitamin D in infectious diseases. He is Co-Director of One Health Aotearoa, an alliance of New Zealand's leading infectious diseases researchers that aims to improve health and well-being through integrated, cross-sectoral and "whole of society" approaches to health hazards.
Prof Graeme Nimmo
Pathology Queensland, Queensland
Professor Graeme Nimmo is State Director of Microbiology for Pathology Queensland and Professor at Griffith University School of Medicine. His research interests include healthcare- and community-associated MRSA, the epidemiology of antimicrobial resistance and molecular typing of healthcare-associated and community-associated pathogens. He is a past-president of the Australian Society for Antimicrobials, Deputy Chair of the Australian Group for Antimicrobial Resistance, and a member of the National Pathology Accreditation Advisory Council. He is a member of the CLSI Working Group on Analysis and Presentation of Cumulative Antimicrobial Susceptibility Data, is a member of the Australian Strategic Technical Advisory Group on Antimicrobial Resistance and is chair of the MRSA Working Group of the International Society for Chemotherapy. He has published over 130 peer-reviewed scientific papers.
Dr Trisha Peel
Monash University, Victoria
Doctor Trisha Peel, MBBS (Hons), FRACP, GradCert (ClinRes), PhD, is an academic infectious diseases and antimicrobial stewardship physician. She is appointed as a Senior Research Fellow and leads the Surgical Infection Research Group, Monash University and Alfred Health. In addition, Dr Peel is the Clinical Lead for the Antimicrobial Stewardship Program at Epworth Healthcare and was involved in the development and implementation of the Stewardship program across the Epworth Healthcare. Dr Peel was awarded her PhD in 2013 and completed her postdoctoral fellowship at the Mayo Clinic, USA, in 2014 under the supervision of Prof Robin Patel. Her research focuses on optimisation of antimicrobial use and patient outcomes in the surgical environment. She has received over $9M in NHMRC funding as a chief investigator on the NHMRC-funded ASAP Trial (APP1120331), a large multicentre randomised-controlled trial examining surgical site infection prevention. In addition, Dr Peel leads the Tertiary Hospital Stream of the NHMRC National Centre for Antimicrobial Stewardship (APP1079625) and is a chief investigator on the NHMRC CRE Total Joint Replacement: Optimising Outcomes, Equity, Cost-effectiveness and Patient Selection (APP1116325) examining surgical stewardship in orthopaedic surgery.
Mr Matthew Rawlins
Fiona Stanley Hospital, Western Australia
Biography to follow.
Dr Katharina Richter
The University of Adelaide, South Australia
Doctor Katharina Richter is an enthusiastic biomedical scientist, dedicated to improving therapies against antibiotic-resistant bacteria and biogilms. Joining the war on superbugs, she develops novel treatments and brings them from the laboratory to the clinic. She has global work and research stints in Germany, Switzerland, Denmark, New Zealand and Australia. With a background in pharmaceutical sciences and a PhD in medicine/applied microbiology, Katharina collaborates with scientists, clinicians and industry partners to ensure a real life impact of her work. Katharina is an ambassador for biomedical research and a passionate science communicator. She engages in numerous public speaking and outreach activities, from leading STEM workshops at schools to organising the Pint of Science festival, making science understandable and fun for everyone.
Dr Jenny Robson
Sullivan Nicolaides Pathology, Queensland
Dr Jenny Robson, MBBS (I Hons), FRACP, FRCPA, FACTM, is an infectious disease physician and microbiologist having worked 30 years in the private sector at Sullivan Nicolaides Pathology (SNP). She was there at the beginning when NAAT testing was introduced and will probably be gone when next gene sequencing becomes routine in clinical microbiology. In the meantime, syndromic molecular panels are what keeps her busy in the molecular laboratory.
Dr Ben Rogers
Monash Health, Victoria
Doctor Ben Rogers is an Infectious Disease specialist at Monash Health and the Monash University School of Clinical Sciences, Victoria. Dr Rogers completed his PhD at the University of Queensland in 2014, researching the epidemiology and management of multi-resistant gram-negative infections in the Australian region. He works in clinical infectious diseases at Monash Health. He runs an active research program including a focus on gram-negative resistance epidemiology, infections in the immunocompromised host and is involved in a number of investigator initiated and industry sponsored clinical trials.
Princess Alexandra Hospital, Queensland
Sean currently serves as lead pharmacist for Infection Management Metro South Health which operates one of Australia’s largest and long-standing OPAT services. He has worked as an infectious diseases pharmacist since 2006 and has gathered extensive experience both aseptic manufacturing and clinical OPAT service delivery. He is a member of the National Infectious Diseases Pharmacists Leadership Group and was part of the authorship team for the inaugural OPAT chapter of the Australian Therapeutic Guidelines.
Dr David Whiley
The University of Queensland, Queensland
Associate Professor David Whiley is a principal research fellow at The University of Queensland and research scientist at Pathology Queensland. Much of his work has focused on the diagnosis and characterisation of Neisseria gonorrhoeae infection and associated antimicrobial resistance. He has authored over 160 articles and in recent years has been leading the NHMRC-funded Gonorrhoea Resistance Assessment via Nucleic Acid Detection (GRAND) studies that aim to enhance gonorrhoea antimicrobial resistance surveillance and tailor antibiotic therapies using molecular methods, particularly in remote settings of Australia.